双氢青蒿素的抗肿瘤作用机制

摘要/Abstract

摘要：双氢青蒿素是青蒿的活性成分之一，可通过与铁离子形成自由基杀伤肿瘤细胞、诱导细胞凋亡、抗肿瘤血管生成、抑制肿瘤侵袭转移、逆转多药耐药、影响细胞内Ca2+浓度、调控细胞周期、调节细胞自噬和免疫系统等方式参与抗肿瘤过程，是潜在可利用的抗肿瘤新药。

彭文苗，付红星，余丽芳，饶智国. 双氢青蒿素的抗肿瘤作用机制[J]. 国际肿瘤学杂志, 2017, 44(6): 448-.

Peng Wenmiao, Fu Hongxing, Yu Lifang, Rao Zhiguo. Mechanism of anti-tumor effect of dihydroartemisinin[J]. Journal of International Oncology, 2017, 44(6): 448-.

［1］ Noori S, Hassan ZM, Farsam V. Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line［J］. Chin J Integr Med, 2014, 20(8): 618-623. DOI: 10.1007/s1165501314542. ［2］ Zhang CZ, Pan Y, Cao Y, et al. Histone deacetylase inhibitors facilitate dihydroartemisinininduced apoptosis in liver cancer in vitro and in vivo［J］. PLoS One, 2012, 7(6): e39870. DOI: 10.1371/journal.pone.0039870. ［3］ Zhang ZS, Wang J, Shen YB, et al. Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy［J］. Oncol Lett, 2015, 10(1): 379-383. DOI: 10.3892/ol.2015.3183. ［4］ Xu G, Zou WQ, Du SJ, et al. Mechanism of dihydroartemisinininduced apoptosis in prostate cancer PC3 cells: an iTRAQbased proteomic analysis［J］. Life Sci, 2016, 157: 1-11. DOI: 10.1016/j.lfs.2016.05.033. ［5］ Wang Q, Wu S, Zhao X, et al. Mechanisms of dihydroartemisinin and dihydroartemisinin/holotransferrin cytotoxicity in Tcell lymphoma cells［J］. PLoS One, 2015, 10(10): e0137331. DOI: 10.1371/journal.pone.0137331. ［6］ Lu JJ, Chen SM, Zhang XW, et al. The anticancer activity of dihydroartemisinin is associated with induction of irondependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells［J］. Invest New Drugs, 2011, 29(6): 1276-1283. DOI: 10.1007/s1063701094818. ［7］ Ba Q, Zhou N, Duan J, et al. Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor1［J］. PLoS One, 2012, 7(8): e42703. DOI: 10.1371/journal.pone.0042703. ［8］ Ontikatze T, Rudner J, Handrick R, et al. Dihydroartemisinin is a hypoxiaactive anticancer drug in colorectal carcinoma cells［J］. Front Oncol, 2014, 4: 116. DOI: 10.3389/fonc.2014.00116. ［9］ D′Alessandro S, Basilico N, Corbett Y, et al. Hypoxia modulates the effect of dihydroartemisinin on endothelial cells［J］. Biochem Pharmacol, 2011, 82(5): 476-484. DOI: 10.1016/j.bcp.2011.06.002. ［10］ Tai X, Cai XB, Zhang Z, et al. In vitro and in vivo inhibition of tumor cell viability by combined dihydroartemisinin and doxorubicin treatment, and the underlying mechanism［J］. Oncol Lett, 2016, 12(5): 3701-3706. DOI: 10.3892/ol.2016.5187. ［11］ Zhao X, Zhong H, Wang R, et al. Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxamediated pathway requiring iron and endoperoxide moiety［J］. Oncotarget, 2015, 6(8): 5582-5596. DOI: 10.18632/oncotarget.3336. ［12］ Lu M, Sun L, Zhou J, et al. Dihydroartemisinin induces apoptosis in colorectal cancer cells through the mitochondriadependent pathway［J］. Tumour Biol, 2014, 35(6): 5307-5314. DOI: 10.1007/s1327701416919. ［13］ Guo L, Dong F, Hou Y, et al. Dihydroartemisinin inhibits vascular endothelial growth factorinduced endothelial cell migration by a p38 mitogenactivated protein kinaseindependent pathway［J］. Exp Ther Med, 2014, 8(6): 1707-1712. DOI: 10.3892/etm.2014.1997. ［14］盛庆寿, 王武, 郭洪武. 双氢青蒿素对原发性肝癌大鼠的治疗作用及机制［J］. 中国实验方剂学杂志, 2014, 20(14): 150-154. DOI: 10.13422/j.cnki.syfjx.2014140150. ［15］ Liu J, Wen X, Liu B, et al. Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP2 and MMP9［J］. Mol Med Rep, 2016, 13(3): 2401-2408. DOI: 10.3892/mmr.2016.4872. ［16］ Zhang S, Ma Y, Jiang J, et al. Inhibition of urokinasetype plasminogen activator expression by dihydroartemisinin in breast cancer cells［J］. Oncol Lett, 2014, 7(5): 1375-1380. DOI: 10.3892/ol.2014.1918. ［17］ Wu B, Hu K, Li S, et al. Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer［J］. Oncol Rep, 2012, 27(1): 101-108. DOI: 10.3892/or.2011.1505. ［18］ Sun N, Zhang Q, Xu C, et al. Molecular regulation of ovarian cancer cell invasion［J］. Tumour Biol, 2014, 35(11): 11359-11366. DOI: 10.1007/s1327701424347. ［19］ Hooft van Huijsduijnen R, Guy RK, Chibale K, et al. Anticancer properties of distinct antimalarial drug classes［J］. PLoS One, 2013, 8(12): e82962. DOI: 10.1371/journal.pone.0082962. ［20］ Lucibello M, Adanti S, Antelmi E, et al. PhosphoTCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells［J］. Oncotarget, 2015, 6(7): 5275-5291. DOI: 10.18632/oncotarget.2971. ［21］ Feng X, Li L, Jiang H, et al. Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatinresistant ovarian cancer cells: involvement of apoptosis and autophagy［J］. Biochem Biophys Res Commun, 2014, 444(3): 376-381. DOI: 10.1016/j.bbrc.2014.01.053. ［22］ Zhao C, Gao W, Chen T. Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine［J］. Apoptosis, 2014, 19(4): 668-681. DOI: 10.1007/s1049501309530. ［23］ Chen T, Chen M, Chen J. Ionizing radiation potentiates dihydroartemisinininduced apoptosis of A549 cells via a caspase8dependent pathway［J］. PLoS One, 2013, 8(3): e59827. DOI: 10.1371/journal.pone.0059827. ［24］ Jacob JA, Salmani JM, Jiang Z, et al. Autophagy: an overview and its roles in cancer and obesity［J］. Clin Chim Acta, 2017, 468: 85-89. DOI: 10.1016/j.cca.2017.01.028. ［25］ Yu X, Luo A, Liu Y, et al. MiR214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy［J］. Mol Cancer, 2015, 14: 208. DOI: 10.1186/s1294301504804. ［26］ Wang Z, Hu W, Zhang JL, et al. Dihydroartemisinin induces autophagy and inhibits the growth of ironloaded human myeloid leukemia K562 cells via ROS toxicity［J］. FEBS Open Bio, 2012, 2: 103-112. DOI: 10.1016/j.fob.2012.05.002. ［27］ Hu W, Chen SS, Zhang JL, et al. Dihydroartemisinin induces autophagy by suppressing NFκB activation［J］. Cancer Lett, 2014, 343(2): 239-248. DOI: 10.1016/j.canlet.2013.09.035. ［28］ Chen SS, Hu W, Wang Z, et al. p8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy［J］. Cancer Biol Ther, 2015, 16(5): 770-779. DOI: 10.1080/15384047.2015.1026477. ［29］李剑. 内质网应激在双氢青蒿素诱导前列腺癌PC3细胞凋亡中的作用研究［D］. 重庆: 重庆医科大学, 2011. ［30］ Noori S, Hassan ZM. Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro, and in vivo［J］. Cell Immunol, 2011, 271(1): 67-72. DOI: 10.1016/j.cellimm.2011.06.008. ［31］ Sun Q, Teong B, Chen IF, et al. Enhanced apoptotic effects of dihydroartemisininaggregated gelatin and hyaluronan nanoparticles on human lung cancer cells［J］. J Biomed Mater Res B Appl Biomater, 2014, 102(3): 455-462. DOI: 10.1002/jbm.b.33023.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

Mechanism of anti-tumor effect of dihydroartemisinin

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价